India on US Special 301 list has no legal effect but shapes trade pressure: GTRI

India has been retained on the Priority Watch List in the US Trade Representative’s (USTR) Special 301 Report on intellectual property protection and enforcement for 2026 but will not have any legal ramifications, according to a GTRI (Global Trade Research Initiative) analysis of the report.The report, released on Thursday, places India alongside China, Russia, Indonesia, Chile and Venezuela on the Priority Watch List. Vietnam has been designated as a Priority Foreign Country (PFC), a category reserved for the most serious IP-related issues.“The PFC identification is reserved by statute for countries with the most egregious IP-related acts, policies, and practices with the greatest adverse impact on relevant US products,” the USTR said, as quoted by PTI, adding that Vietnam has not made meaningful progress in negotiations on intellectual property protection commitments.India has remained on the Priority Watch List since the 1990s, reflecting long-standing differences with the United States over intellectual property policy, particularly in the pharmaceutical sector, the GTRI report noted.According to the GTRI analysis, the Special 301 listing has no legal effect but is used as a pressure tool in trade negotiations and policy engagement. It can influence future demands and discussions between trading partners.

Citing the nature of the listing, GTRI said: “The Special 301 listing has no legal effect but shapes future trade negotiations and demands.”The report highlighted that India’s inclusion is linked to US concerns over pharmaceutical-related intellectual property rules, including Section 3(d) of the Patents Act, compulsory licensing provisions, and absence of data exclusivity for pharmaceuticals. India, however, maintained that its intellectual property regime is WTO-compliant and designed to ensure access to affordable medicines, while balancing innovation and public health objectives.The GTRI report stated that India supplies nearly 20 per cent of global generic medicines, and that its patent framework is structured to prevent evergreening and ensure affordability.It further noted that provisions such as Section 3(d) and compulsory licensing have been upheld within India’s legal framework and used sparingly, reflecting policy restraint. "Accepting US demands could weaken India’s generics industry and raise drug costs worldwide," it added.The analysis also flagged broader US concerns over enforcement gaps, including piracy, counterfeiting, delays in patent processing, and absence of a standalone trade secrets law, while noting India’s position that enforcement capacity has improved and protections exist under existing laws.The United States said it will continue engagement with Priority Watch List countries and may intensify bilateral consultations, with the possibility of action under Section 301 of the US Trade Act, 1974, in certain cases.According to GTRI, the Special 301 process is not legally binding but serves as an administrative mechanism used by the US to shape trade discussions and policy expectations.